The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

New psoriasis drug Zoryve approved. How to use & why Black American participation in clinical trials is vital for health ...

In children, eczema often looks like a dry ... that causes a ring-shaped rash around the hairline. Meanwhile, scalp psoriasis tends to cause thicker, drier scales than eczema.

Children ages 6 years and older with moderate ... Everyone in this study already tried at least one topical treatment for scalp psoriasis, but it did not help. The average age of the people ...

The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

The FDA approved a supplemental new drug application for roflumilast topical foam 0.3% for the treatment of plaque psoriasis ...

The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and ...

Some children continue to have excessive dry ... It can be difficult to tell the difference between mild scalp psoriasis and seborrhoeic dermatitis. In psoriasis there appear to be big patches ...

People with scalp psoriasis may experience itchy ... The infection is highly transmissible and common among young children. Although mild impetigo may clear up independently, prompt treatment ...

A total of 432 patients (56.3% women) aged 12 and older with psoriasis on the scalp and body were randomly assigned to two groups, one of which used roflumilast foam 0.3% once a day for eight ...

Once-daily roflumilast foam, 0.3% (Zoryve) significantly improved scalp and body symptoms of plaque psoriasis in a phase III trial. Improvements in scalp itch were also greater for patients ...